These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

76 related items for PubMed ID: 3875671

  • 21. The lupus inhibitor: a study of its heterogeneity.
    Coots MC, Miller MA, Glueck HI.
    Thromb Haemost; 1981 Dec 23; 46(4):734-9. PubMed ID: 7330826
    [Abstract] [Full Text] [Related]

  • 22. Circulating anticoagulant against factor XI in psoriasis.
    Rustgi RN, LaDuca FM, Tourbaf KD.
    J Med; 1982 Dec 23; 13(4):289-301. PubMed ID: 6957528
    [Abstract] [Full Text] [Related]

  • 23. High molecular weight kininogen protects human plasma kallikrein and factor XIa against inactivation by plasma protease inhibitors.
    Schapira M, Scott CF, Colman RW.
    Trans Assoc Am Physicians; 1981 Dec 23; 94():190-7. PubMed ID: 6979819
    [No Abstract] [Full Text] [Related]

  • 24. Acquired factor XI inhibitor in systemic lupus erythematosus--case report and literature review.
    Bortoli R, Monticielo OA, Chakr RM, Palominos PE, Rohsig LM, Kohem CL, Xavier RM, Brenol JC.
    Semin Arthritis Rheum; 2009 Aug 23; 39(1):61-5. PubMed ID: 18519152
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Regulation of the coagulant activity and surface binding of high molecular weight kininogen.
    Colman RW, Silver LD, Purdon AD, Chang JJ, Scott CF.
    Trans Assoc Am Physicians; 1984 Aug 23; 97():113-23. PubMed ID: 6336014
    [Abstract] [Full Text] [Related]

  • 27. Transfusion-induced specific anti-factor XI inhibitor in a patient with previously unrecognized factor XI deficiency.
    Musclow CE, Amato D, Ofosu F, Armstrong AL, Abbott D.
    Am J Clin Pathol; 1988 Mar 23; 89(3):418-22. PubMed ID: 3258118
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Prothrombin is a cofactor for the binding of factor XI to the platelet surface and for platelet-mediated factor XI activation by thrombin.
    Baglia FA, Walsh PN.
    Biochemistry; 1998 Feb 24; 37(8):2271-81. PubMed ID: 9485373
    [Abstract] [Full Text] [Related]

  • 32. Phosphorylation of coagulation factor XI by a casein kinase released by activated human platelets increases its susceptibility to activation by factor XIIa and thrombin.
    Ekdahl KN, Elgue G, Nilsson B.
    Thromb Haemost; 1999 Oct 24; 82(4):1283-8. PubMed ID: 10544914
    [Abstract] [Full Text] [Related]

  • 33. [A patient with hemorrhage originating from an unknown coagulation pathway inhibitor].
    Komiyama Y, Munakata M, Masuda M, Kagawa H, Fukuhara S, Takahashi H.
    Rinsho Byori; 2000 Dec 24; 48(12):1086-92. PubMed ID: 11215416
    [Abstract] [Full Text] [Related]

  • 34. Thrombin-mediated activation of factor XI results in a thrombin-activatable fibrinolysis inhibitor-dependent inhibition of fibrinolysis.
    Von dem Borne PA, Bajzar L, Meijers JC, Nesheim ME, Bouma BN.
    J Clin Invest; 1997 May 15; 99(10):2323-7. PubMed ID: 9153272
    [Abstract] [Full Text] [Related]

  • 35. [Hemorrhage after tonsillectomy in a patient with PTA and Hageman factor deficiency: clinico-therapeutic considerations].
    Lecco V, Orlandi GF.
    Ann Laringol Otol Rinol Faringol; 1968 May 15; 67(2):275-80. PubMed ID: 5757319
    [No Abstract] [Full Text] [Related]

  • 36. IgG reactivity to phospholipid-bound beta(2)-glycoprotein I is the main determinant of the fraction of lupus anticoagulant activity quenched by addition of hexagonal (II) phase phospholipid in patients with the clinical suspicion of antiphospholipid-antibody syndrome.
    Safa O, Crippa L, Della Valle P, Sabbadini MG, Viganò D'Angelo S, D'Angelo A.
    Haematologica; 1999 Sep 15; 84(9):829-38. PubMed ID: 10477458
    [Abstract] [Full Text] [Related]

  • 37. The possible role of platelets in bypassing the contact phase of blood coagulation.
    Walsh PN, Tuszynski GP, Greengard JS, Griffin JH.
    Haematologia (Budap); 1984 Sep 15; 17(2):169-78. PubMed ID: 6534825
    [Abstract] [Full Text] [Related]

  • 38. Contact activation of Hageman factor and the interaction of Hageman factor and plasma thromboplastin antecedent.
    Haanen C, Morselt G, Schoenmakers J.
    Thromb Diath Haemorrh; 1967 May 31; 17(3-4):307-20. PubMed ID: 5626768
    [No Abstract] [Full Text] [Related]

  • 39. Acquired factor XI inhibitors in congenitally deficient patients.
    Schnall SF, Duffy TP, Clyne LP.
    Am J Hematol; 1987 Dec 31; 26(4):323-8. PubMed ID: 3687930
    [Abstract] [Full Text] [Related]

  • 40. Inhibition of Hageman factor activation.
    Nossel HL, Rubin H, Drillings M, Hsieh R.
    J Clin Invest; 1968 May 31; 47(5):1172-80. PubMed ID: 5645860
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 4.